Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $123.2 billion, finds itself at a critical juncture as it navigates ...

with VX-880 and VX-264, represent a potentially transformative approach to a chronic condition affecting millions worldwide. Furthermore, Vertex's pipeline includes promising candidates for AMKD ...

Vertex is also evaluating VX-880 in a phase 3 study as a potential cure for severe type 1 diabetes. Fourth, I expect Vertex will likely further expand its pipeline through business development deals.

Vertex is also evaluating VX-880 in a phase 3 study as a potential cure for severe type 1 diabetes. Fourth, I expect Vertex will likely further expand its pipeline through business development deals.

Vertex Machineries Limited (VML) was incorporated as a Private Limited Company on 12th September 1994 under the companies Act, 1956 and converted into a public Limited Company by passing a special ...

Lati­go Bio­ther­a­peu­tics, a non-opi­oid pain biotech look­ing to ride the waves cre­at­ed by Ver­tex Phar­ma­ceu­ti­cals’ pain drug ap­proval last month, is tar­get­ing up to … ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

AlgoTx’s mid-stage stumble on Tuesday comes after Vertex earlier this month won the FDA’s approval for Journavx, an inhibitor of the NaV1.8 voltage-gated sodium channel that marks the first new ...